Cargando…
Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700274/ https://www.ncbi.nlm.nih.gov/pubmed/34977601 http://dx.doi.org/10.1016/S2665-9913(21)00418-5 |
| _version_ | 1784620717662273536 |
|---|---|
| author | Boekel, L Wolbink, G J |
| author_facet | Boekel, L Wolbink, G J |
| author_sort | Boekel, L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8700274 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87002742021-12-28 Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients Boekel, L Wolbink, G J Lancet Rheumatol Comment Published by Elsevier Ltd. 2022-03 2021-12-23 /pmc/articles/PMC8700274/ /pubmed/34977601 http://dx.doi.org/10.1016/S2665-9913(21)00418-5 Text en © 2021 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Boekel, L Wolbink, G J Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients |
| title | Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients |
| title_full | Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients |
| title_fullStr | Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients |
| title_full_unstemmed | Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients |
| title_short | Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients |
| title_sort | rituximab during the covid-19 pandemic: time to discuss treatment options with patients |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700274/ https://www.ncbi.nlm.nih.gov/pubmed/34977601 http://dx.doi.org/10.1016/S2665-9913(21)00418-5 |
| work_keys_str_mv | AT boekell rituximabduringthecovid19pandemictimetodiscusstreatmentoptionswithpatients AT wolbinkgj rituximabduringthecovid19pandemictimetodiscusstreatmentoptionswithpatients |